ABSTRACT
Objective:To explore the characteristics of diagnosis, treatment and prognosis of intermittent testicular torsion (ITT) in children.Methods:Retrospective review was conducted for the clinical data of 9 ITT cases from April 2014 to December 2019. The average age of all patients was 11.9 years (range 4.7-13.9 years). The involved side was left ( n=4), right ( n=4) and bilateral ( n=1). The main symptoms included severe pain of rapid onset and rapid resolution associated with nausea and lower abdominal pain ( n=1). The average number of painful episode was 2.4(1-5). There was a number of 1 painful episode in 4 emergency operative cases and more than 1 in 4 elective operative cases and 1 emergency operative cases. One patient of recurrent scrotal pain was relieved by manual detorsion. Among the five emergency operative cases, scrotal swelling and tenderness were found on the affected side, and the cremasteric reflex disappeared. Ultrasonic examination showed that two had absent testicular flow, one had decreased testicular flow, one had normal testicular flow with swelling epididymis and one with torsion of spermatic cord above testis. While among the 4 elective operative cases, the lie of the affected testis with cremasteric reflex was low on physical examination in all patients, compared with the contralateral testis. Atrophy of the affected testis were found in one case and horizontal lie in another one. The duration of prehospital symptoms ranged 4-24 hours during acute presentation in the 5 emergency patients, and 5-24 months in the 4 elective patients. All patients underwent testicular surgical exploration and bilateral orchidopexy. Results:Surgical exploration revealed no testicular ischemic infarction, and the rate of testicular salvage was 100%. A bell-clapper deformity (BCD) was found on all the affected testis and 2 contralateral testis as well. The median time of follow-up time was 10 months (range 1-69 months). No recurrence of testicular pain and other complications was found. Except for one case of testicular atrophy in the affected side before operation, the testicles of all patients recovered well without testicular atrophy.Conclusions:Intermittent testicular torsion is mainly manifested as repeated episodes of sudden onset unilateral scrotal pain that could be spontaneously resolved. The positive clinical findings include a horizontal position of the testes while standing and discrepancy in size of the testes. The ultrasonic examination is diversified because testicular torsion can be spontaneously relieved. Although the rate of testicular salvage is high in ITT, surgical exploration and bilateral scrotal orchiopexy should be carried out as early as possible to prevent recurrent painful episodes and testicular ischemic damage.
ABSTRACT
OBJECTIVE:To prepare Idebenone solid dispersion,and to investigate its dissolution rate in vitro. METHODS:Us-ing Poloxamer 407(P407)as carrier,the influence of preparation methods(solvent method,melting method)and the ratio of the drug to P407(1∶1,1∶3,1∶8)on the dissolution of drug were investigated by single factor design. The state of idebenone in ma-trix of solid dispersion was further determined by using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRD). RESULTS:Idebenone solid dispersion prepared by solvent method(the ratio of the drug to poloxamer was 1∶3)showed dissolution rate of 80%. The majority of idebenone existed in the solid dispersion at amorphous forms or molecular state. CONCLU-SIONS:Idebenone solid dispersions with high dissolution rate in vitro is prepared successfully.
ABSTRACT
S-1 is an upgraded product of tegafur and UFT. Compared with 5-FU, it has stronger anticancer activity, and relative rare gastrointestinal adverse reaction. Many clinical studies have demonstrated S-1 has very good efficacy and safety in patients with advanced gastric cancer. The efficacy of single S-1 has been approved better than other available anti-cancer drugs in the treatment of gastric cancer, and similar to combination regimens such as cisplatin plus fluorouracil.
ABSTRACT
Objective To study the antitumor effects of exosomes derived from heat-shocked E.G7-OVA tumor cells in vivo. Methods Exosomes derived from E.G7-OVA tumor cells were isolated and purified by serial centrifugation and sucrose gradients ultracentrifugation. Exosomes from heat-shocked or non-heat-shocked E.G7-OVA tumor cells were named as Exo/HS and Exo correspondingly. Exosomes were viewed by electron microscopy. Protein components of exosomes were detected by Western blot. Exo, Exo/ HS or PBS were injected into mice before injection of E.G7-OVA tumor cells, and antitumor effects were ob-served in each group. Mouse model bearing E.G7-OVA tumor cells were established to examine immunother-apy effects of Exo or Exo/HS. Cytotoxity of spleen CTL were measured by LDH. Results Exosomes con-tained bi-layer membrane and their diameters are between 40 nm and 100 nm under electron microscopy. The Western blot results showed that HSC70, HSP70, HSP60, HSP90, MHC Ⅰ and OVA were present in both Exo and Exo/HS. However, Exo/HS contained more HSP70 and MHC Ⅰ than Exo. Protective antitu-mor immunity suggested that tumor-free survival (90 days) rate in Exo/HS vaccinated mice was significantly higher than those in Exo or PBS vaccinated mice (50%, 20%, 0%, P<0.01). Therapeutic antitumor effects showed that immunization by Exo/HS resulted in dramatically enhanced antitumor effects when com-pared to the Exo- or PBS-treated groups (P<0.01). CTL results showed that immunization with Exo/HS in-duced higher level of OVA-specific CTL responses as compared with those from Exo or PBS (P<0.01). Conclusion Exosomes derived heat-shocked E.G7-OVA tumor cells may be used as potent cancer vaccine.
ABSTRACT
Objective: To observe the safety and clinical efficacy of tumor antigen-pulsed dendritic cell(DC) vaccine in treatment of advanced malignant tumor.Methods: Ninety-one patients with non-small cell lung cancer,colon and rectal cancer,melanoma,renal carcinoma,breast cancer and other malignant tumors were enrolled in this study.All patients met the selecting standard and signed informed consent.Human dendritic cells were obtained from peripheral blood monocytes by culturing them with granulocyte macrophage-colony stimulating factor and interleukin-4.DC vaccine was prepared from tumor antigen pulsed immature dendritic cells in vitro.Patients received the vaccine therapy once every week and one cycle was defined as once every week for 3 weeks.Results: All the patients received 96 cycles of DC vaccine treatment.Symptoms of toxicity included fever,shivering,aching pain of muscle,asthenia,itching,stifle and transient fatigue;most of the symptoms automatically recovered.Clinical efficacy of the treatment was evaluated in 76 patients.Thirty-one of the 76 patients were stable after treatment and 45 were in progressive situation,with the clinical benefiting rate being 40.8%.Eighty-five patients were followed up.The median time for progression was 2.6 months;the overall survival time was 0.9-30.6 months;and the median survival period was 4.5 months,with the one year survival rate being 9.2%.Conclusion: The results suggest that the DC vaccine therapy is well tolerated in treating patients with advanced malignant tumors and has satisfactory clinical benefit;the clinical value of DC vaccine therapy needs to be further observed.
ABSTRACT
Purpose:To evaluate the immediate therapeutic effects and toxicities of intraperitoneal versus intravenous chemotherapy in advanced gastric cancer.Methods:Sixty one patients were treated with intravenous chemotherapy of leucovorin (CF) , fluorouracil ( 5 Fu) etoposide (Vp16) and intraperitoneal chemotherapy of cis platinum (DDP) in advanced gastric cancer. The short term effects and toxicities were observed.Results:The overall response rate was 57.4% and the complete response rate was 9.8% of the 61 patients .Leukopenia was observed in 95.1%, thrombocy topentia were observed in 27.8% of patients . Other side effects were uncommon.Conclusions:Intravenous chemotherapy of ELF and intraperitoneal chemotherapy of DDP were effective for advanced gastric cancer and are worthy to be further studied.
ABSTRACT
Objective:To study the in vivo anti-tumor effect of exosomes (Exo) combined with bacillus Calmette-Gu?rin vaccine(BCG). Methods:Exo was isolated and purified from culture supernatant of E.G7-OVA tumor cells by density gradient centrifugation. Protein components of Exo were detected by Western blotting. Exo,BCG,Exo combined with BCG (Exo+BCG) or PBS were pre-injected into mice before injection of E.G7-OVA cells,and the anti-tumor effects were observed in each group. Mouse model bearing E.G7-OVA cells was established to examine the immuno-therapy effects of Exo with or without BCG. Cytotoxity of spleen CTL was measured by LDH in different groups. Results:Exo derived from E.G7-OVA cells contained HSP60,OVA,HSC70 and CD63 as detected by Western blotting. Tumor-free rate at 90 d was significantly higher in Exo+BCG vaccinated mice than those in Exo or BCG vaccinated mice as measured by immuno-protective assay (60% vs 20% or 0%,P
ABSTRACT
Objective To enhance the oral bioavailability of breviscapine and investigate the feasibility of preparing the proliposome of breviscapine by fluidized bed coating method. Methods The fluidized bed coating method was used to prepare breviscapine proliposome and ultrafiltration-HPLC was applied to determination of the encapsulation efficiency. The influence factors on encapsulation efficiency including carriers, drug-lipid weight ratio, inlet air temperature, spray rate, and spray air volume were investigated. Results When the carrier was sorbitol and the drug-lipid weight ratio was under 1∶3, the encapsulation efficiency could be higher. Inlet air temperature, spray rate, and spray air volume had some effects on the encapsulation efficiency. By the method, the fluidity of the proliposome granules was well and the particle size distribution ratio of them was uniform; the mean particle size of liposomal formulation of breviscapine after rehydration was 98 nm, and the encapsulation efficiency was (63.1?2.8)% (n=3). Conclusion It is feasible to prepare the breviscapine proliposome with fluidized bed coating method.